A Phase I/II Multicenter, Open-Label Study of YM155 Plus Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors.

Trial Profile

A Phase I/II Multicenter, Open-Label Study of YM155 Plus Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Jul 2015

At a glance

  • Drugs Docetaxel; Prednisone; Sepantronium bromide
  • Indications Prostate cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 20 May 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 20 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Sep 2009 Planned end date changed from 1 Dec 2009 to 1 Apr 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top